Global pharma major Lupin Limited has announced the strategic carve-out of its consumer healthcare business, LupinLife Consumer Healthcare Ltd. (LCH), into a wholly owned subsidiary, effective July 1, 2025.
This initiative aligns with the aspiration to establish a specialised consumer healthcare entity, with an enhanced focus on India's rapidly growing self-care market.
Since its inception in 2017, LupinLife Consumer Healthcare has emerged as a strong over-the-counter (OTC) healthcare business with a portfolio of scientifically formulated and trusted brands such as Softovac®, Beplex Forte®, Corcium® and Aptivate®.
Anil Kaushal will lead the new independent entity as Chief Executive Officer. This restructuring will enable enhanced focus with targeted investments, leading to increased consumer impact, market expansion, and accelerated growth.
Speaking on the development, Nilesh Gupta, Managing Director, Lupin said, "This strategic move reinforces our mission of developing high-impact businesses that drive sustained value. LCH exemplifies our unwavering dedication to patient-centric care and service to consumers.”
Anil V Kaushal, CEO LupinLife Consumer Healthcare commented, "This carve-out marks an exciting new chapter in our consumer healthcare journey. We are committed to offering world-class OTC products and wellness solutions for Indian consumers. LCH is well-positioned to scale with agility, innovate with intent, and expand access to wellness solutions across India.”
